echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > The Lancet: AstraZenecon's chimpanzee adenovirus vector COVID-19 vaccine induces a strong immune response in older adults

    The Lancet: AstraZenecon's chimpanzee adenovirus vector COVID-19 vaccine induces a strong immune response in older adults

    • Last Update: 2020-11-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Research data for Phase II of the chimpanzee adenovirus vector COVID-19 vaccine AZD1222 (also known as ChAdOx1 nCoV-19), developed in collaboration with AstraZeneta and Oxford University, published online today in The Lancet Lancet, show that AZD1222 induces a strong immune response in older adults and is more resistant than in younger adults.
    there are generally no pre-existing and medium antibodies against chimpanzee-type adenovirus in humans, so the vaccine developed with chimpanzee-type adenovirus vectors is often better than the common human serum adenovirus vectors.
    AstraZenecon chimpanzee adenovirus vector COVID-19 vaccine action schematic (Photo:) The Lancet published data from the ongoing Phase II/III trial, which recruited 560 healthy adults aged 18 and over, divided into three subgroups by age: 160 aged 18 to 55, 160 aged 56 to 69, and 160 over 70 years of age.
    subjects were randomly assigned different doses of AZD1222 or a controlled vaccine.
    similar results for immune responses of all ages showed that on the 28th day after receiving two doses of the vaccine, participants in three age groups had similar levels of IgG against SARS-CoV-2 spike protein in their bodies, and that the moderate antibody titration was similar in three age groups.
    further data showed that 208 of the 209 patients who received the second dose of the vaccine had a meso-antibody response 14 days after the dose was increased.
    T-cell response peaked on the 14th day after a single dose of AZD1222 was injected in all age groups.
    lead researcher Maheshi Ramasamy, of the Oxford Vaccine Group, said: "In our study, it was very encouraging to see large numbers of antibodies and T-cell responses in older adults.
    " Older people had better tolerance for safety, with 88 per cent of the 18-55 age group reporting a local reaction after the initial vaccination of two doses of AZD1222 subjects;
    In addition, 86 per cent of the participants in the 18-55 age group had a systemic response, 77 per cent of the participants in the 56-69 age group had a reaction, and only 65 per cent of the participants in the 70-year-old age group had a systemic response.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.